Table 3.
No. | Pathways | Driver genes assocated pathway (BARF, NRAS, c-KIT, MITF) | IL8 | FGFR3 | PTPRF | TNC | SHC4 | CXCL13 | EGFR | WNT4 | FGFR2 | PPP2R2C | CHP2 | COL11A1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa04010 | MAPK signaling pathway | ✓ | ✓ | ✓ | ✓ | ||||||||
2 | hsa04012 | ERBB signaling pathway | ✓ | ✓ | ||||||||||
3 | hsa04060 | cytokine-cytokine receptor interaction | ✓ | ✓ | ✓ | |||||||||
4 | hsa04062 | chemokine signaling pathway | ✓ | ✓ | ✓ | |||||||||
5 | hsa04115 | p53 signaling pathway | ||||||||||||
6 | hsa04144 | endocytosis | ✓ | ✓ | ✓ | |||||||||
7 | hsa04360 | axon guidance | ✓ | |||||||||||
8 | hsa04370 | VEGF signaling pathway | ✓ | |||||||||||
9 | hsa04510 | focal adhesion | ✓ | ✓ | ✓ | ✓ | ||||||||
10 | hsa04530 | tight junction | ✓ | |||||||||||
11 | hsa04540 | GAP junction | ✓ | |||||||||||
12 | hsa04650 | natural killer cell mediated cytotoxicity | ✓ | ✓ | ||||||||||
13 | hsa04660 | T cell receptor signaling pathway | ✓ | |||||||||||
14 | hsa04662 | B cell receptor signaling pathway | ✓ | |||||||||||
15 | hsa04720 | long-term potentiation | ✓ | |||||||||||
16 | hsa04722 | neurotrophine signaling pathway | ✓ | |||||||||||
17 | hsa04810 | regulation of actin cytoskeleton | ✓ | ✓ | ✓ | |||||||||
18 | hsa04910 | insulin signaling pathway | ✓ | ✓ | ||||||||||
19 | hsa04912 | GnRH signaling pathway | ✓ | |||||||||||
20 | hsa04916 | melanogenesis | ✓ | |||||||||||
21 | hsa05160 | hepatitis C | ✓ | ✓ | ✓ | |||||||||
22 | hsa05166 | HTLV-1 infection | ✓ | |||||||||||
23 | hsa05200 | pathways in cancer | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||
24 | hsa05212 | pancreatic cancer | ✓ | |||||||||||
25 | hsa05213 | endometrial cancer | ✓ | |||||||||||
26 | hsa05214 | glioma | ✓ | ✓ | ||||||||||
27 | hsa05215 | prostate cancer | ✓ | ✓ | ||||||||||
28 | hsa05218 | melanoma | ✓ | |||||||||||
29 | hsa05219 | bladder cancer | ✓ | ✓ | ✓ | |||||||||
30 | hsa05220 | chronic myeloid leukemia | ✓ | |||||||||||
31 | hsa05223 | non-small cell lung cancer | ✓ |